Background:Glioblastoma multiforme(GBM)is recognized as the most lethal and most highly invasive tumor.The high likelihood of treatment failure arises fromthe presence of the blood-brain barrier(BBB)and stemcells arou...Background:Glioblastoma multiforme(GBM)is recognized as the most lethal and most highly invasive tumor.The high likelihood of treatment failure arises fromthe presence of the blood-brain barrier(BBB)and stemcells around GBM,which avert the entry of chemotherapeutic drugs into the tumormass.Objective:Recently,several researchers have designed novel nanocarrier systems like liposomes,dendrimers,metallic nanoparticles,nanodiamonds,and nanorobot approaches,allowing drugs to infiltrate the BBB more efficiently,opening up innovative avenues to prevail over therapy problems and radiation therapy.Methods:Relevant literature for this manuscript has been collected from a comprehensive and systematic search of databases,for example,PubMed,Science Direct,Google Scholar,and others,using specific keyword combinations,including“glioblastoma,”“brain tumor,”“nanocarriers,”and several others.Conclusion:This review also provides deep insights into recent advancements in nanocarrier-based formulations and technologies for GBM management.Elucidation of various scientific advances in conjunction with encouraging findings concerning the future perspectives and challenges of nanocarriers for effective brain tumor management has also been discussed.展开更多
The persistent global pandemic,COVID-19,stems from the pathogenic influence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),yielding an unprecedented worldwide crisis.With reference to a WHO report,the ...The persistent global pandemic,COVID-19,stems from the pathogenic influence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),yielding an unprecedented worldwide crisis.With reference to a WHO report,the count of COVID-19 cases had exceeded 754 million by February 03,2023.Intriguingly,emerging research has spotlighted the intricate interplay of gut microbiota and mitochondrial entities,acting as potent immunomodulatory factors at the cellular and molecular levels.This interconnection operates through a series of dynamic mechanisms.SARS-CoV-2 infection perturbs the delicate equilibrium of gut microbiota,leading to dysbiosis—a signature biomarker.This imbalance is intrinsically linked to exacerbated COVID-19 progression.Mechanistically,this microbial dysbiosis triggers aberrant immune responses,marked by cytokine storms,while also inducing mitochondrial dysfunction.Mitochondrial activities crucial to energy production and immunoregulation are compromised.This dual perturbation of microbiota and mitochondria contributes to disease severity.This review provides a comprehensive overview of these interconnected mechanisms,illuminating how microbiota-mitochondria interplay serves as both a diagnostic biomarker and a promising therapeutic target in the realm of COVID-19.展开更多
文摘Background:Glioblastoma multiforme(GBM)is recognized as the most lethal and most highly invasive tumor.The high likelihood of treatment failure arises fromthe presence of the blood-brain barrier(BBB)and stemcells around GBM,which avert the entry of chemotherapeutic drugs into the tumormass.Objective:Recently,several researchers have designed novel nanocarrier systems like liposomes,dendrimers,metallic nanoparticles,nanodiamonds,and nanorobot approaches,allowing drugs to infiltrate the BBB more efficiently,opening up innovative avenues to prevail over therapy problems and radiation therapy.Methods:Relevant literature for this manuscript has been collected from a comprehensive and systematic search of databases,for example,PubMed,Science Direct,Google Scholar,and others,using specific keyword combinations,including“glioblastoma,”“brain tumor,”“nanocarriers,”and several others.Conclusion:This review also provides deep insights into recent advancements in nanocarrier-based formulations and technologies for GBM management.Elucidation of various scientific advances in conjunction with encouraging findings concerning the future perspectives and challenges of nanocarriers for effective brain tumor management has also been discussed.
文摘The persistent global pandemic,COVID-19,stems from the pathogenic influence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),yielding an unprecedented worldwide crisis.With reference to a WHO report,the count of COVID-19 cases had exceeded 754 million by February 03,2023.Intriguingly,emerging research has spotlighted the intricate interplay of gut microbiota and mitochondrial entities,acting as potent immunomodulatory factors at the cellular and molecular levels.This interconnection operates through a series of dynamic mechanisms.SARS-CoV-2 infection perturbs the delicate equilibrium of gut microbiota,leading to dysbiosis—a signature biomarker.This imbalance is intrinsically linked to exacerbated COVID-19 progression.Mechanistically,this microbial dysbiosis triggers aberrant immune responses,marked by cytokine storms,while also inducing mitochondrial dysfunction.Mitochondrial activities crucial to energy production and immunoregulation are compromised.This dual perturbation of microbiota and mitochondria contributes to disease severity.This review provides a comprehensive overview of these interconnected mechanisms,illuminating how microbiota-mitochondria interplay serves as both a diagnostic biomarker and a promising therapeutic target in the realm of COVID-19.
